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HIF-1 activation induces doxorubicin resistance in
MCF7 3-D spheroids via P-glycoprotein
expression: a potential model of the chemo-
resistance of invasive micropapillary carcinoma of
the breast
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Abstract
Background: Invasive micropapillary carcinoma (IMPC) of the breast is a distinct and aggressive variant of luminal
type B breast cancer that does not respond to neoadjuvant chemotherapy. It is characterized by small
pseudopapillary clusters of cancer cells with inverted cell polarity. To investigate whether hypoxia-inducible factor-1
(HIF-1) activation may be related to the drug resistance described in this tumor, we used MCF7 cancer cells
cultured as 3-D spheroids, which morphologically simulate IMPC cell clusters.
Methods: HIF-1 activation was measured by EMSA and ELISA in MCF7 3-D spheroids and MCF7 monolayers.
Binding of HIF-1a to MDR-1 gene promoter and modulation of P-glycoprotein (Pgp) expression was evaluated by
ChIP assay and FACS analysis, respectively. Intracellular doxorubicin retention was measured by spectrofluorimetric
assay and drug cytotoxicity by annexin V-FITC measurement and caspase activity assay.
Results: In MCF7 3-D spheroids HIF-1 was activated and recruited to participate to the transcriptional activity of
MDR-1 gene, coding for Pgp. In addition, Pgp expression on the surface of cells obtained from 3-D spheroids was
increased. MCF7 3-D spheroids accumulate less doxorubicin and are less sensitive to its cytotoxic effects than
MCF7 cells cultured as monolayer. Finally, HIF-1a inhibition either by incubating cells with 3-(5’-hydroxymethyl-2’-
furyl)-1-benzylindazole (a widely used HIF-1a inhibitor) or by transfecting cells with specific siRNA for HIF-1a
significantly decreased the expression of Pgp on the surface of cells and increased the intracellular doxorubicin
accumulation in MCF7 3-D spheroids.
Conclusions: MCF7 breast cancer cells cultured as 3-D spheroids are resistant to doxorubicin and this resistance is
associated with an increased Pgp expression in the plasma membrane via activation of HIF-1. The same
mechanism may be suggested for IMPC drug resistance.
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Background
Invasive micropapillary carcinoma (IMPC) of the breast
is a rare and aggressive histologic subtype of infiltrating
breast carcinoma. It is characterized by small pseudopa-
pillary clusters of cancer cells surrounded by clear
spaces with loose fibrocollagenous stroma [1]. It has
been reported that most IMPC are estrogen receptor
(ER)-positive breast cancers displaying aberrant localiza-
tion of the luminal glycoprotein mucin 1 (MUC1) at the
stromal-basal surface of micropapillae, corresponding to
an inversion of cell polarity [2]. IMPC frequently shows
advanced stage at diagnosis, high incidences of lympho-
vascular invasion and axillary lymph node metastases,
and high rates of local recurrence with short disease-
free survival [3,4]. In addition, IMPC harbors genetic
aberrations consistent with those of the luminal B sub-
group of ER positive breast cancers [5], which are asso-
ciated with poor outcome. Because of its highly
aggressive behavior, preoperative neoadjuvant che-
motherapy (NAC) has been considered for IMPC [6].
Interestingly, Alvarado-Cabrero et al. have recently
reported that among a series of breast cancers treated
with NAC none of the IMPC had a pathologic complete
response to therapy, defined as the absence of any
microscopic evidence of tumor in the mastectomy speci-
men and axillary lymph node dissection. Indeed, these
patients had extensive residual invasive carcinoma after
neoadjuvant therapy, and the disease was multifocal in
most of the cases [7]. To our knowledge no data have
been reported on the molecular basis of this phenom-
enon that may be related, at least in part, to multidrug
resistance (MDR) of the tumor emboli.
The development of MDR is a major obstacle to cancer
treatment. MDR in cancer cells produces resistance to
the cytotoxic effects of numerous antineoplastic drugs
that are structurally and mechanistically unrelated, and
this significantly decreases the efficacy of cancer che-
motherapy [8]. MDR may be either constitutive or
acquired and can be mediated by several different
mechanisms including target alterations, enhanced DNA
repair, evasion of apoptosis, induction of drug-metaboliz-
ing enzymes, alterations in drug uptake and active trans-
port of drugs out of cells [9]. Energy-dependent efflux of
chemotherapeutic drugs out of cells is to a great extent
mediated by transmembrane transporters belonging to
the ATP-binding cassette (ABC) proteins superfamily,
which use ATP hydrolysis as an energy source to trans-
port a variety of structurally diverse molecules across
membranes irrespective of concentration gradient [10].
Among the 48 members of the human ABC transporters
family, P-glycoprotein (Pgp, ABCB1) is the most widely
studied. A great deal of studies has coupled increased
expression of Pgp to impairment of chemotherapy
response and lower patient survival [11].
There is a general consensus that hypoxia in the cen-
tre of solid tumors dramatically decreases the chemo-
sensitivity of tumor cells and that experimental hypoxia
promotes drug resistance to anticancer agents in a vari-
ety of cell lines [12]. A central component of hypoxic
adaptation is hypoxia-inducible factor-1 (HIF-1), the
transcription factor that leads hypoxic cells to up-regu-
late proteins that promote survival and increases aggres-
siveness of hypoxic tumor cells [13,14]. When adequate
oxygen (O2) is present, the subunit HIF-1a becomes
hydroxylated at several proline residues and this leads to
ubiquitination and proteasomal degradation. However,
when O2 is absent this molecule survives and translo-
cates to the nucleus, where it forms an heterodimer
with HIF-1b. The HIF-1 heterodimer is a transcription
factor recognized by at least 100 hypoxia response ele-
ment (HRE) sites on chromosomes [15]. In particular, it
has been recently demonstrated that the activation of
HIF-1 is associated with an increase of Pgp expression
and the occurrence of MDR in tumor cells [16-20].
In this study, to investigate the role of drug resistance
in the aggressive behavior of tumor cell clusters encoun-
tered in IMPC, we used a model of three-dimensional
cell culture, defined as 3-D spheroids, which has been
described previously [21]. Here we show that the ER-
positive MCF7 breast cancer cells cultured as 3-D
spheroids are resistant to doxorubicin and that this
resistance is associated with an increased Pgp expression
at the plasma membrane via activation of HIF-1.
Methods
Cells
MCF7 human breast cancer epithelial cells were cul-
tured in a 1:1 mixture of DMEM/HAM’S F12 medium
(Gibco, Paisley, UK) supplemented with 10% (v/v) fetal
bovine serum (FBS) (Sigma-Aldrich S.r.l., Milan, Italy),
1% penicillin/streptomycin (Sigma), 1% L-glutamine
(Sigma), and maintained in a humidified incubator at
37°C, 5% CO2 and 20% O2. For the different experimen-
tal conditions, aliquots of MCF7 monolayer cells were
either cultured in a humidified incubator at 37°C, 5%
CO2, and 20% O2 (basal condition), or 3% O2 for 24 h
(hypoxic exposure). Hypoxic exposure of MCF7 cells
was used as a positive control of HIF-1 activation since
we did not measure the gradient in O2 in MCF7 3-D
spheroids. Preliminary experiments were performed to
set the pressure of O2 necessary to detect HIF-1a
expression by immunoblot assay and HIF-1 DNA-bind-
ing activity by EMSA and DNA binding ELISA (data
not shown). We have determined that a decrease of O2
concentration to 3% was sufficient to induce HIF-1 acti-
vation in MCF7 cells. Other aliquots of MCF7 mono-
layers cells were transfected with MDR-1 gene,
previously cloned in pCDNA3, using jetPEI transfection
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reagent (Poly-plus Transfection, Euroclone, Pero, Italy)
according to the manufacturer’s instructions in order to
obtain an overexpression of Pgp, or incubated with
human neutrophil elastase (Calbiochem, San Diego, CA,
21 U/mg) in order to obtain MCF7 3-D spheroids, as
described previously [21]. Briefly, 5 × 106 MCF7 cells
were plated in 100-mm diameter Petri dishes and sup-
plemented with DMEM/HAM’S F12 medium containing
1% FBS and 20 μg/ml human neutrophil elastase. Com-
pact multicellular MCF7 3-D spheroids with smooth
margins were observed after a 24-48 h-incubation.
Spheroids of various sizes were obtained and pooled to
perform the different experiments.
Western blot analysis
Nuclear extracts (60 μg), obtained with the Nuclear
Extraction Kit (Active Motif, Vinci-Biochem, Florence,
Italy), were separated by SDS-PAGE, transferred to
PVDF membrane (Immobilon-P, Millipore, Bedford,
MA). PVDF membrane was blocked in Tris-buffered sal-
ine solution (TBS)-nonfat dry milk 5% overday at 4°C
and probed with anti-HIF-1a mouse mAb (diluted 1:500
in TBS-nonfat dry milk 5%, cat # 610959, BD Bios-
ciences, San Jose, CA) and anti-PCNA mouse mAb
(diluted 1:500 in TBS-nonfat dry milk 5%, sc-56, Santa
Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts (10 μg) were used to detect HIF-1a
translocation. The probe containing the HIF-1a oligonu-
cleotide consensus sequence was labeled with [g-32P]
ATP (Perkin Elmer) (3000 Ci/mmol, 250 μCi), using T4
polynucleotide kinase (Roche, Basel, Switzerland). The
sequence of oligonucleotide was: 5’-TCTGTACGTGAC-
CACACTCACCTC-3’; 3’-AGACATGCACTGGTGT-
GAGTGGAG-5’. The DNA-protein complex was
separated on a non-denaturating 4% polyacrylamide gel
in TBE buffer (0.4 Mol/L Tris, 0.45 Mol/L boric acid,
0.5 Mol/L EDTA, pH 8.0). After electrophoresis, the gel
was dried and autoradiographed by exposure to X-ray
film.
DNA binding enzyme-linked immunosorbent assay
(ELISA)
Nuclear extracts (10 μg), obtained with the Nuclear
Extraction Kit (Active Motif, Vinci-Biochem), were used
to detect HIF-1 capacity to bind an HRE by TransAM
ELISA Kit (Active Motif, Vinci-Biochem) according to
the manufacturer’s instructions. Briefly, samples were
added to a 96-well plate, on which there was an immo-
bilized oligonucleotide containing an HRE (5’-
TACGTGCT-3’) from the EPO gene, incubated with
anti-HIF-1a antibody (diluted 1:1000 in Antibody Bind-
ing Buffer), subjected to a horseradish peroxidase-
conjugated anti-mouse antibody (diluted 1:1000 in Anti-
body Binding Buffer) and then incubated with Develop-
ing Solution, until the blue color development reaction
was performed. Absorbance was read on a Packard
EL340 microplate reader (Bio-Tek Instruments,
Winooski, VT) at 450 nm with a reference wavelength
of 655 nm; the absorbance values were expressed as mU
optical density/μg nuclear proteins.
Semi-quantitative polymerase chain reaction
Total RNA was obtained by the guanidinium thiocya-
nate-phenol-chloroform method [22]. Two μg of total
RNA were reversely transcribed into cDNA, in a final
volume of 20 μl, using the QuantiTect Reverse Tran-
scription Kit (Qiagen, Germantown, USA) according to
the manufacturer’s instructions. Semi-quantitative PCR
was carried out in a final volume of 50 μl with specific
primers for the quantitation of pyruvate dehydrogenase
kinase isozyme 1 (PDK1, p1 primer: 5’-GAAG-
CAGTTCCTGGACTTCG-3’; p2 primer: 5’-ACCAATT
GAACGGATGGTGT-3’; 56°C, 153 bp), phosphoglyce-
rate kinase 1 (PGK1, p1 primer: 5’-TCTCATGGATG
AGGTGGTGA-3’; p2 primer: 5’-CTTCCAGGAGCTC-
CAAACTG-3’; 56°C, 152 bp), vascular endothelial
growth factor (VEGF, p1 primer: 5’-ATCTTCAAGCC
ATCCTGTGTGC-3’; p2 primer: 5’-GCTCACCGC
CTCGGCTTGT-3’; 62°C, 488 bp) and ribosomal protein
S14 genes (p1 primer: 5’-AGGTGCAAGGAGCTGGG-
TAT-3’; p2 primer: 5’-TCCAGGGGTCTTGGTCC-
TATTT-3’; 60°C, 77 bp). PCR amplification was 1 cycle
of denaturation at 95°C for 3 min, 30 cycles of denatura-
tion at 94°C for 30 s, annealing for 30 s, synthesis at 72°
C for 1 min. Differences in expression levels between
the different experimental conditions (MCF7 control
cells, MCF7 hypoxic cells and MCF7 3-D spheroids in
the presence or absence of YC-1) were large enough to
be detected by semi-quantitative PCR. To determine the
assay range, we plotted increasing numbers of PCR
cycles against the integrated optical density obtained
from computer-aided densitometry (Image J 1.43u Java
1.6.0_10, National Institutes of Health, Bethesda, MD,
USA, http://imagej.nih.gov/ij) (data not shown), as
described previously [23]. The PCR products were sepa-
rated on a 4% agarose gel and visualized with ethidium
bromide.
Chromatin immunoprecipitation assay (ChIP)
The chromatin immunoprecipitation assay was done fol-
lowing the recommendations of the manufacturer
(Upstate, Billerica, MA) with some modifications.
Briefly, cells were plated in 100-mm diameter dishes (6
× 106 cells per dish); after 24 h, they were incubated
with formaldehyde (final concentration, 1%) for 10 min
at 37°C to cross-link proteins to DNA. The cross-linking
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reaction was quenched by the addition of one-tenth
volume of 1.25 mol/L glycine, giving 125 mmol/L final
concentration. Cells were washed twice with ice-cold
PBS 1X, resuspended in radioimmunoprecipitation assay
buffer [150 mMol/L NaCl, 1% NP40, 0.5% deoxycholate,
0.1% SDS, 5 mMol/L EDTA, 50 mMol/L Tris-HCl (pH
8.0)] containing 1 mMol/L PMSF, 1 μg/mL aprotinin,
and 1 μg/mL pepstatin A, and kept on ice for 30 min.
Then, cell lysates were sonicated on ice with a Hielscher
UP200S ultrasound sonicator (3 × 40 s, amplitude 40%;
Hielscher Ultrasonics GmbH, Germany) until cross-
linked chromatins were sheared to yield DNA fragments
between 200 and 1,000 bp. One tenth of whole lysate
was used to quantify the amount of DNA present in dif-
ferent samples and considered as “input DNA”. Super-
natants were incubated with salmon sperm DNA/
protein agarose-50% slurry to reduce non-specific back-
ground. Immunoprecipitation was then done overnight
at 4°C with 5 μg of anti-HIF-1a antibody [rabbit poly-
clonal, (H-206): sc-10790, Santa Cruz Biotechnology] or
without antibody (negative control). These supernatants
were supplemented with 5 Mol/L NaCl and heated over-
night at 65°C to reverse protein-DNA cross-links. The
immunocomplexes were further treated with DNase-and
RNase-free proteinase K, and DNA was purified by phe-
nol/chloroform extraction and ethanol precipitation.
Semi-quantitative PCR was performed with specific pri-
mers flanking the putative HRE within the promoter
region of the human MDR-1 gene (named “Pgp+”, p1
primer: 5’-GGAGCAGTCATCTGTGGTGA-3’; p2 pri-
mer: 5’-CTCGAATGAGCTCAGGCTTC-3’), primers
flanking a MDR-1 promoter region that does not con-
tain HRE (named “Pgp-”, used as a negative control, p1
primer: 5’-GAAGGTCTTCCCAGTAACCTACC-3’; p2
primer: 5’-GCCAGAGTTGAGAAGTTTAGCC-3’), pri-
mers flanking the HRE of the human vascular endothe-
lial growth factor (VEGF) promoter (used as a positive
control, p1 primer: 5’-GCCTCTGTCTGCCCAGCTGC-
3’; p2 primer: 5’-GTGGAGCTGAGAACGGGAAGC-3’),
as reported previously [24]. Differences in expression
levels between the different experimental conditions
(MCF7 control cells, MCF7 hypoxic cells and MCF7 3-
D spheroids in the presence or absence of YC-1) were
large enough to be detected by semi-quantitative PCR.
To determine the assay range, we plotted increasing
numbers of PCR cycles against the integrated optical
density obtained from computer-aided densitometry
(Image J 1.43u Java 1.6.0_10, National Institutes of
Health, Bethesda, MD, USA, http://imagej.nih.gov/ij)
(data not shown), as described previously [23]. Cycling
for “Pgp+” and “Pgp-” was: 1 cycle at 95°C for 7 min,
followed by 37 cycles at 94°C for 1 min, annealing at 56°
C for 1 min, extension at 72°C for 1 min; cycling for
VEGF was: 1 cycle at 95°C for 7 min, followed by 37
cycles at 94°C for 1 min, annealing at 64°C for 1 min,
extension at 72°C for 1 min. The PCR products were
separated on a 4% agarose gel and visualized with ethi-
dium bromide.
HIF-1a siRNA transfection
Cells were transfected with specific HIF-1a siRNA in
order to obtain a knockdown (KD) phenotype. Cells
were plated in a six well tissue culture plate (200,000
cells/well) and cultured in antibiotic-free DMEM/
HAM’S F12 medium containing 10% FBS. After 24 h
cells were washed once with siRNA Transfection Med-
ium (Santa Cruz Biotechnology) and incubated for 6 h
with 1 ml siRNA transfection medium, containing 6 μl
of siRNA Transfection Reagent (sc-29528, Santa Cruz
Biotechnology), and 400 nM/L of HIF-1a siRNA (sc-
35561, Santa Cruz Biotechnology). In each set of experi-
ments one dish was treated with 400 nM/L of Control
siRNA-A (Santa Cruz Biotechnology), a non-targeting
20-25 nucleotides siRNA designed as a negative control,
instead of HIF-1a siRNA. At the end of the incubation,
1 ml of DMEM/HAM’S F12 medium containing 1%
penicillin/streptomycin and 20% FBS was added for 24
h. Subsequently, MCF7 cell monolayers under normoxic
conditions (MCF7 control cells) and MCF7 cell mono-
layers under hypoxic conditions were washed and cul-
tured for 48 h in DMEM/HAM’S F12 medium with 1%
penicillin/streptomycin and 10% FBS. To form spher-
oids, 4 wells of a six well tissue culture plate were tryp-
sinized and plated in 60-mm diameter Petri dishes and
supplemented with DMEM/HAM’S F12 medium con-
taining 1% FBS and 20 μg/ml human neutrophil elastase.
Compact multicellular MCF7 3-D spheroids with
smooth margins were observed after a 24-48 h-incuba-
tion. To verify the siRNA efficacy, cells were lysed and
the expression of HIF-1a protein was analysed by Wes-
tern blotting using an anti-HIF-1a mouse monoclonal
antibody (mAb) (diluted 1:500 in TBS-nonfat dry milk
5%, cat # 610959, BD Biosciences). To assess the siRNA
specificity for HIF-1a, we checked the expression of
PCNA, a product of an housekeeping gene in both
transfected and untransfected cells (data not shown).
Silenced cells were indicated as HIF-1a KD 3-D spher-
oids, HIF-1a KD Monolayer Hypoxia, HIF-1a KD
Monolayer Normoxia Pgp+, and HIF-1a KD Monolayer
Normoxia.
Pgp expression
Pgp proteins were labeled on the surface of non-per-
meabilized cells and quantified by FACS analysis. Cells
were fixed with cold 2% paraformaldehyde solution for
15 min, washed in PBS 1X and then resuspended in
PBS 1X supplemented with 0.25% BSA/0.01% sodium
azide containing an anti-Pgp polyclonal antibody [1:20
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diluted, Mdr (H-241): sc-8313, Santa Cruz Biotechnol-
ogy] or an isotype-matched negative control (DakoCyto-
mation, Glostrup, Denmark) for 45 min at 4°C. Cells
were then washed 3 times with PBS 1X/0.25% BSA/
0.01% sodium azide and incubated with a FITC-conju-
gated anti-rabbit antibody (1:400 diluted) for 30 min at
4°C. Samples were then collected and analyzed using a
FACSCalibur CellQuest (Becton Dickinson). Cells were
electronically gated according to their light-scattering
properties to exclude cell debris. Ten thousand cells
were analyzed at each experimental point. The percen-
tage of cells positive for Pgp was calculated by the Cell
Quest software (Becton Dickinson).
Doxorubicin accumulation
Cellular doxorubicin content was evaluated by fluori-
metric assay. Before every test, cells were washed and
then incubated in fresh medium containing 3 μMol/L
doxorubicin (Sigma) for 18 h. Intracellular doxorubicin
content was measured using a Perkin-Elmer LS-5 fluori-
meter (Perkin Elmer, Shelton, CT) at 475 nm (excita-
tion) and 553 nm (emission); fluorescence was
converted in ng of doxorubicin per mg of cellular pro-
tein, using a calibration curve prepared previously. The
protein content of cell monolayers was assessed with the
bicinchoninic acid (BCA) protein assay kit (Sigma). To
evaluate the contribution of Pgp in the drug resistance
of MCF7 3-D spheroids, we measured the drug accumu-
lation in the presence 100 μMol/L Pgp inhibitor verapa-
mil hydrochloride (Sigma).
Detection of apoptosis
Induction of apoptosis due to the cytotoxic effect of
doxorubicin was evaluated by Annexin V-fluorescein
isothiocyanate (FITC) apoptosis detection kit (Sigma)
and by measuring the caspase activity:
Annexin V-FITC measurement
Cells were incubated in the absence or presence of dox-
orubicin (3 μMol/L for 18 h), washed with phosphate-
buffered saline solution (PBS) 1X, detached with trypsin/
EDTA, and resuspended in 1 ml of binding buffer (100
mMol/L HEPES/NaOH, 140 mMol/L NaCl, 25 mMol/L
CaCl2, pH 7.5). These cell suspensions were then incu-
bated for 10 min with 5 μl annexin V-FITC conjugate
(0.05 mg/ml). Cells were washed 3 times with fresh PBS
1X and fluorescence of each sample was evaluated. The
fluorescence level of annexin V was recorded using a
FACSCalibur system (Becton Dickinson, Bedford, MA)
reading the emission selected by a 530 nm band pass fil-
ter; the percentage of cells positive for annexin V was cal-
culated by the Cell Quest software (Becton Dickinson).
Results are expressed as average of percent of control
values obtained from triplicate experiments.
Caspase activity assays
The caspase activity was evaluated by fluorogenic assay
(Sigma). Cells and spheroids were incubated with doxor-
ubicin (3 μMol/L for 18 h) in the absence or in the pre-
sence of YC-1 (5 μMol/L) washed with PBS 1X, lysed in
1 ml of lysis buffer (20 mMol/L HEPES/KOH, 10 mMol/
L KCl, 1.5 mMol/L MgCl2, 1 mMol/L EGTA, 1 mMol/L
EDTA, 1 mM/L DTT, 1 mM/L PMSF, 10 μg/ml leupep-
tin, pH 7.5), detached with a scraper and centrifuged at
13000 r.p.m for 15 min at 4°C, the supernatant was col-
lected and the protein content was assessed with the
BCA protein assay kit (Sigma). Briefly, cell lysates (10 μg)
were incubated with 20 μMol/L of substrate in a caspase
substrate buffer (25 mM/L HEPES, 0.1% w/v CHAPS,
10% w/v sucrose, 10 mM/L DTT, 0.1% w/v egg albumin,
pH 7.5) for 1 h at 37°C, then the reaction was stopped
with 0.1% w/v ice-cold TCA. The content of substrate
cleavage was measured using a Perkin-Elmer LS-5 fluori-
meter (Perkin Elmer) at 380 nm (excitation) and 460 nm
(emission); fluorescence was converted in μmol AMC (7-
amino-4-methyl coumarin) per mg of cellular protein,
using a calibration curve prepared previously.
Immunohistochemistry analysis
On formalin fixed paraffin embedded sections of cells
and tissues, we performed morphological and immuno-
histochemical analysis to evaluate the similarities
between MCF7-3D spheroids and IMPC. Cells were
fixed in 10% buffered formalin for 5 min, transferred in
a tube and centrifuged for 5 min at 800 rpm. Cell pellets
were rinsed 2 times in PBS and re-fixed in 10% formalin
for 15 min. Cell blocks were prepared following the
standard processing (vacuum processor, Leica ASP
300S, Leica AG, Switzerland) and paraffin embedded.
For all specimens, 3 μm thick sections were cut. Both
MCF7 cell pellets and breast biopsies from patients with
IMPC of the breast (used as a positive control of
MUC1, CD44 and p53 expression) were processed for
immunohistochemical staining. Sections were deparaffi-
nized and submitted to endogenous peroxidase activity
blocking with 3% hydrogen peroxide for 7 min. An anti-
gen retrieval procedure was performed using citrate buf-
fer solution, pH 6.0, for 40 min. Sections were then
incubated with an anti-MUC1 monoclonal antibody
(mAb) (clone Ma695) (Novocastra, Newcastle Upon
Tyne, UK) diluted 1:100, for 30 min. Cells were then
washed 3 times with PBS 1X and incubated with anti-
mouse labeled polymer HRP-conjugated (Envision +
System, Dako Glostrup, Denmark) for 30 min. Then
3,3-diaminobenzidine (DAB, Dako) was used as a chro-
mogen to reveal antibody binding and slides were coun-
terstained in Mayer’s haematoxylin (BioGenex
Laboratories) for 30 seconds, dehydrated and mounted.
Tissue sections and MCF7 3D-spheroids were
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immunostained for HIF-1a using the anti-HIF-1a poly-
clonal antibody (ab2185, Abcam, Cambridge, UK) with
the automated stainer BenchMark XT (Ventana-Roche
F, Hoffmann-La Roche Ltd, Tucson, AZ). In addition, to
evaluate the expression of biological markers of aggres-
siveness, MCF7 control cells and MCF7 3D-spheroids
were stained using the BenchMark XT by anti-CD44
(DF1485, DAKO), a pleiotropic molecule involved in
cell adhesion and tumor metastasis formation, and anti-
p53 antibodies (DO-7 prediluted Ventana), since CD44
and p53 are two molecules frequently expressed in
IMPC [25,26]. All incubations were performed at room
temperature. Control experiments included incubation
of sections or cells with non-immune isotypic control
antibodies or the omission of primary antibodies fol-
lowed by the appropriate labeled secondary antibodies.
Statistical analysis
Measurements were performed in triplicate. All data in
text and figures are provided as means ± SEM. The
results were analyzed by a one-way Analysis of Variance
(ANOVA) and Tukey’s test. p < 0.05 was considered
significant.
Results
HIF-1 is activated in MCF7 3-D spheroids
Cells cultured as 3-D spheroids are associated with a
microenvironment characterized by gradients in O2, pH,
and nutrients [27,28]. Therefore, we investigated
whether in vitro MCF7 3-D spheroid formation may
lead to the activation of HIF-1, a key component of
hypoxic adaptation. We first showed with western blot
analysis that HIF-1a was present into the nucleus of
cells from MCF7 3-D spheroids and MCF7 cell mono-
layers under hypoxic conditions (MCF7 hypoxic cells,
used as a positive control of HIF-1 activation), whereas
HIF-1a was undetectable in MCF7 cell monolayers
under normoxic conditions (MCF7 control cells) (Figure
1a). We then observed with EMSA that HIF-1a was
translocated into the nucleus of cells from MCF7 3-D
spheroids and MCF7 hypoxic cells, whereas MCF7 con-
trol cells showed undetectable levels of HIF-1a (Figure
1b). These results were confirmed by DNA binding
ELISA: MCF7 control cells exhibited a minimal activa-
tion of HIF-1, while MCF7 3-D spheroids and MCF7
hypoxic cells showed a significant increase in the tran-
scription factor activation, defined by an increased capa-
city to bind HRE (Figure 1c). The incubation of cells
with a widely used HIF-1a inhibitor, 3-(5’-hydroxy-
methyl-2’-furyl)-1-benzylindazole (YC-1) (5 μMol/L for
24 h), which induces a decrease in HIF-1a accumulation
by down-regulating HIF-1a mRNA translation [29], sig-
nificantly decreased HIF-1 activation in both MCF7 3-D
spheroids and MCF7 hypoxic cells, while, as expected, it
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Figure 1 Effects of MCF7 3-D spheroid formation on HIF-1
activation. A: Representative gel of Western blot analysis of HIF-1a
performed on nuclear cellular extracts (see Materials and Methods
for details) in MCF7 cell monolayers under normoxic conditions
(Monolayer Normoxia), MCF7 cell monolayers under hypoxic
conditions (Monolayer Hypoxia), MCF7 3-D spheroids (Spheroids),
and Cos-7 cells stimulated with CoCl2 (used as a positive control of
HIF-1a expression). B: Representative gel of EMSA for detection of
HIF-1a nuclear translocation. Monolayer Normoxia: MCF7 cell
monolayers under normoxic conditions; Spheroids: MCF7 3-D
spheroids; and Monolayer Hypoxia: MCF7 cell monolayers under
hypoxic conditions as positive control (3% O2 for 24 h). In each
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had no effect in MCF7 control cells (Figure 1c). We
finally observed with RT-PCR analysis that the expres-
sion of the genes PDK1, PGK1, and VEGF, which are
well-known targets of HIF-1, was increased in MCF7 3-
D spheroids and MCF7 hypoxic cells compared to
MCF7 control cells (Figure 2).
Binding of HIF-1a to MDR-1 gene promoter and increased
expression of Pgp in MCF7 3-D spheroids and in MCF7
hypoxic cells
We then evaluated in MCF7 3-D spheroids and in
MCF7 hypoxic cells whether HIF-1a may bind to a
putative HRE within the promoter region of the MDR-1
gene, increasing Pgp transcription, by a ChIP assay.
After precipitation of cell lysates with a specific anti-
HIF-1a antibody, the MDR-1 gene promoter containing
a HRE and VEGF gene promoter (an established HIF-1
target gene) were amplified by PCR with specific pri-
mers. In MCF7 3-D spheroids and in MCF7 hypoxic
cells, occupancy of HIF-1a at the MDR-1 (Figure 3a)
and VEGF (Figure 3b) gene promoters was higher than
in MCF7 control cells. We checked in all conditions
tested that chromatin precipitated with an anti-HIF-1a
antibody showed no enrichment of the MDR-1 promo-
ter region that does not contain a HRE (Figure 3c).
Moreover, incubation of cells with YC-1 (5 μMol/L for
24 h) was able to reduce the binding of HIF-1a to
MDR-1 and VEGF gene promoters in MCF7 3-D spher-
oids and MCF7 hypoxic cells (Figure 3a and 3b). These
results suggest that, after activation, HIF-1 is recruited
to participate to the transcriptional activity of MDR-1
gene in both MCF7 3-D spheroids and MCF7 hypoxic
cells.
Pgp protein levels were then quantified by FACS ana-
lysis on the surface of non-permeabilized cells. The per-
centage of positive cells for Pgp was significantly higher
in MCF7 3-D spheroids, in MCF7 hypoxic cells, and in
MCF7 cells transfected with MDR-1 gene (MCF7 Pgp +
cells, used as a positive control of Pgp expression) com-
pared to the percentage of positive cells for Pgp in
MCF7 control cells (Figure 4a and 4b). The inhibition of
HIF-1a either by incubating cells with YC-1 (5 μMol/L
for 24 h) (Figure 4a and 4b) or by transfecting cells with
specific siRNA for HIF-1a (Figure 5a and 5b) signifi-
cantly decreased the Pgp surface expression in both
MCF7 3-D spheroids and MCF7 hypoxic cells, while it
had no effect in MCF7 control cells or in MCF7 Pgp +
cells. These results suggest that in both MCF7 3-D
spheroids and MCF7 hypoxic cells, surface Pgp expres-
sion is associated with HIF-1 activation.
MCF7 3-D spheroids are more resistant to doxorubicin
than MCF7 cell monolayers under normoxic conditions:
they accumulate less doxorubicin and are less sensitive to
its cytotoxic effects
After an 18 h-incubation with 3 μMol/L doxorubicin,
MCF7 3-D spheroids as well as MCF7 hypoxic cells and
MCF7 Pgp + cells accumulated significantly less of the
drug than MCF7 control cells (Figure 6). The inhibition
of HIF-1a either by incubating cells with YC-1 (5 μMol/
L for 24 h) (Figure 6a) or by transfecting cells with
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Figure 2 Relative expression of PDK1, PGK1, VEGF (well-known
HIF-1 target genes) and S14 (housekeeping gene) checked by
semi-quantitative PCR analysis in MCF7 cell monolayers under
normoxic conditions (Monolayer Normoxia); MCF7 3-D
spheroids (Spheroids); and MCF7 cell monolayers under
hypoxic conditions (Monolayer Hypoxia). The figure is
representative of three similar experiments.
experiment one lane was loaded with bisdistilled water only (H2O)
in place of cellular extracts as negative control. This figure is
representative of three similar experiments. C: Detection of HIF-1
activation by DNA binding ELISA in MCF7 cell monolayers under
normoxic conditions (Monolayer Normoxia); MCF7 3-D spheroids
(Spheroids); and MCF7 cell monolayers under hypoxic conditions
(Monolayer Hypoxia). Cell monolayers and spheroids were incubated
in the absence (white columns) or in the presence (hatched
columns) of 5 μM YC-1 for 24 h. ***, P < 0.0001 versus Monolayer
Normoxia without YC-1; °°°, P < 0.0001 versus Spheroids or
Monolayer Hypoxia without YC-1. This figure is representative of
three similar experiments, performed in duplicate.
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Figure 4 Effects of MCF7 3-D spheroid formation and hypoxia
on Pgp expression. Pgp protein levels were labeled on the surface
of non-permeabilized cells and were quantified by FACS analysis as
reported in Materials and Methods. A: Pgp protein levels were
higher in MCF7 3-D spheroids (Spheroids), in MCF7 hypoxic cells
(Monolayer Hypoxia), and in MCF7 cells transfected with MDR-1
gene (Monolayer Normoxia Pgp+) compared to Pgp protein levels
in MCF7 control cells (Monolayer Normoxia). The incubation of cells
with YC-1 (5 μMol/L for 24 h) decreased the Pgp surface expression
in both MCF7 3-D spheroids and MCF7 hypoxic cells, while it had
no effect in Pgp + cells. These figure panels are representative of
three similar experiments. B: The percentage of positive cells for Pgp
in MCF7 cells cultured as monolayers under normoxic conditions
(Monolayer Normoxia), 3-D spheroids (Spheroids), monolayers under
hypoxic conditions (Monolayer Hypoxia), and transfected with MDR-
1 gene (Monolayer Normoxia Pgp+). Cells and spheroids were
incubated in the absence (white columns) or in the presence
(hatched columns) of 5 μM YC-1 for 24 h. ***, P < 0.0001 versus
Monolayer Normoxia without YC-1; °°°, P < 0.0001 versus Spheroids
or Monolayer Hypoxia without YC-1.
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Figure 3 HIF-1a binds to HRE within MDR-1 and VEGF gene
promoters in MCF7 3-D spheroids. The binding of HIF-1a on
MDR-1 and VEGF gene promoters were measured by ChIP assay as
described in Materials and Methods. A: PCR analysis for the MDR-1
gene promoter region containing a HRE was performed on
immunoprecipitation samples (IP) with anti-HIF-1a antibody and
with purified total input DNA (input DNA) from MCF7 control cells
(Monolayer Normoxia); MCF7 hypoxic cells (Monolayer Hypoxia); and
MCF7 3-D spheroids (Spheroids). B: PCR analysis for the VEGF gene
promoter (an established HIF-1 target gene) was performed on
immunoprecipitation samples with anti-HIF-1a antibody and with
purified total input DNA from MCF7 control cells; MCF7 hypoxic
cells; and MCF7 3-D spheroids. C. PCR analysis for the MDR-1 gene
promoter region that does not contain a HRE was performed on
immunoprecipitation samples (IP) with anti-HIF-1a antibody and
with purified total input DNA from MCF7 control cells; MCF7
hypoxic cells; and MCF7 3-D spheroids. Cell monolayers and
spheroids were incubated in the absence (-) or in the presence (+)
of 5 μM YC-1 for 24 h. The figures are representative of three similar
experiments.
Doublier et al. BMC Cancer 2012, 12:4
http://www.biomedcentral.com/1471-2407/12/4
Page 8 of 15
specific siRNA for HIF-1a (Figure 6b) increased the
doxorubicin accumulation in both MCF7 3-D spheroids
and MCF7 hypoxic cells to a level comparable to the
one of MCF7 control cells, while it had no effect in
MCF7 control cells and, as expected, in MCF7 Pgp +
cells. To evaluate the contribution of Pgp in the drug
resistance of MCF7 3-D spheroids, we measured drug
accumulation in the presence (+) or absence (-) of the
Pgp inhibitor verapamil [30]. Verapamil (V, 100 μMol/
L) increased intracellular doxorubicin content in MCF7
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Figure 5 Effects of HIF-1a silencing on Pgp expression in MCF7
3-D spheroids and MCF7 hypoxic cells. Pgp protein levels were
labeled on the surface of non-permeabilized cells and were
quantified by FACS analysis as reported in Materials and Methods.
A: Pgp protein levels were higher in MCF7 3-D spheroids
(Spheroids), in MCF7 hypoxic cells (Monolayer Hypoxia), and in
MCF7 cells transfected with MDR-1 gene (Monolayer Normoxia Pgp
+) compared to Pgp protein levels in MCF7 control cells (Monolayer
Normoxia). The transfection of cells with specific siRNA for HIF-1a
(HIF-1a knockdown, KO) significantly decreased the Pgp surface
expression in both MCF7 3-D spheroids and MCF7 hypoxic cells,
while it had no effect in Pgp + cells. Silenced cells were indicated
as HIF-1a KD 3-D Spheroids, HIF-1a KD Monolayer Hypoxia and HIF-
1a KD Monolayer Normoxia Pgp+. These figure panels are
representative of three similar experiments. B: The percentage of
positive cells for Pgp in MCF7 cells cultured as monolayers under
normoxic conditions (Monolayer Normoxia), 3-D spheroids
(Spheroids), monolayers under hypoxic conditions (Monolayer
Hypoxia), and transfected with MDR-1 gene (Monolayer Normoxia
Pgp+). Cells and spheroids were transfected with 400 nM/L of HIF-
1a (hatched columns) or transfected with vehicle alone (white
columns). ***, P < 0.0001 versus Monolayer Normoxia transfected
with vehicle alone; °°°, P < 0.0001 versus Spheroids or Monolayer
Hypoxia transfected with vehicle alone.
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Figure 6 Effects of 3-D spheroid formation and hypoxia on the
doxorubicin accumulation in MCF7 cells. A: Cells and spheroids
were incubated with 3 μMol/L doxorubicin for 18 h, in the absence
(white columns) or in the presence (hatched columns) of 5 μmol/L
YC-1 for 24 h (6 h alone and 18 h together with doxorubicin). Drug
accumulation was then measured in MCF7 cell monolayers under
normoxic conditions (Monolayer Normoxia), MCF7 3-D spheroids
(Spheroids), MCF7 cell monolayers under hypoxic conditions
(Monolayer Hypoxia), and MCF7 cells transfected with MDR-1 gene
(Monolayer Normoxia Pgp+). ***, P < 0.0001 versus Monolayer
Normoxia without YC-1; *, P < 0.05 versus Monolayer Normoxia
without YC-1; °°°, P < 0.0001 versus Spheroids or Monolayer Hypoxia
without YC-1. B: Cells and spheroids were transfected with 400 nM/
L of HIF-1a (hatched columns) or transfected with vehicle alone
(white columns), and incubated with 3 μMol/L doxorubicin for 18 h.
Drug accumulation was then measured in MCF7 cell monolayers
under normoxic conditions (Monolayer Normoxia), MCF7 3-D
spheroids (Spheroids), MCF7 cell monolayers under hypoxic
conditions (Monolayer Hypoxia), and MCF7 cells transfected with
MDR-1 gene (Monolayer Normoxia Pgp+). ***, P < 0.0001 versus
Monolayer Normoxia transfected with vehicle alone; *; °°°, P <
0.0001 versus Spheroids or Monolayer Hypoxia transfected with
vehicle alone.
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3-D spheroids (-V: 1840.66 ± 70.58; +V: 4247.30 ±
201.62 ng doxorubicin/mg protein) when compared to
MCF7 control cells (-V: 4125.76 ± 89.75; +V: 4088.24 ±
86.96 ng doxorubicin/mg protein, P < 0.0001) (Addi-
tional file 1: Figure S1). We also measured the cytotoxic
effects of the drug through the detection of cell apopto-
sis by annexin V-FITC staining. The percentage of
annexin V-positive cells exposed to doxorubicin (3
μMol/L, 18 h) was significantly higher in MCF7 control
cells than in MCF7 3-D spheroids and in MCF7 hypoxic
cells, suggesting in these latter a protection against early
apoptosis (Figure 7a). In the presence of YC-1 (5 μMol/
L for 24 h), the percentage of annexin V-positive cells
increased significantly in MCF7 3-D spheroids and in
MCF7 hypoxic cells to a level comparable to the one
observed in MCF7 control cells (Figure 7a). It has been
reported that doxorubicin induces apoptosis by activat-
ing caspase-9 in cancer cells [31], we thus evaluated by
fluorogenic assays caspase activity in MCF7 cells
exposed to doxorubicin (3 μMol/L, 18 h). We demon-
strated that caspase-9 activity was significantly higher in
MCF7 control cells than in MCF7 3-D spheroids and in
MCF7 hypoxic cells (Figure 7b and 7c). In the presence
of YC-1 (5 μMol/L for 24 h), caspase-9 activity
increased significantly in MCF7 3-D spheroids and in
MCF7 hypoxic cells to a level comparable to the one
observed in MCF7 control cells (Figure 7b and 7c).
Taken together, these results suggest that MCF7 3-D
spheroid formation induced a resistance to doxorubicin,
at least in part, via surface Pgp expression.
Immunophenotypical similarities between of MCF7 3-D
spheroids and micropapillary carcinoma
MUC1, a membrane glycoprotein of the apical cell bor-
ders, is aberrantly over-expressed by most human breast
carcinomas [32]. In IMPC at difference from other
breast cancers, MUC1 is expressed on the basal surface
of the cell clusters [33,34]. To evaluate whether to the
morphological similarity observed between elastase-
induced MCF7 3-D spheroids (Figure 8a) and IMPC of
the breast (Figure 8b) corresponded also an immuno-
phenotypical similarity, we assessed MUC1 expression
in MCF7 3-D spheroids. We demonstrated that in
MCF7 3-D spheroids MUC1 was expressed along the
outer cell surface of the clusters (Figure 8c) similarly to
IMPC (Figure 8d). Both the MCF7 3-D spheroids and
the IMPC showed nuclear expression of HIF-1a (Figure
8e and 8f). In addition, we showed that markers of bio-
logical aggressiveness known to be expressed in IMPC
were also present in MCF7 3-D spheroids: CD44 was
expressed in MCF7 3-D spheroids (while absent in
MCF7 control cells) and p53 expression was increased
compared to the one of MCF-7 control cells (Figure 9).
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Figure 7 A: Evaluation of early apoptosis, measured as
percentage of cells positive for annexin V by FACS analysis.
Cells and spheroids were incubated with 3 μMol/L doxorubicin for
18 h, in the absence (white columns) or in the presence (hatched
columns) of 5 μMol/L YC-1 for 24 h (6 h alone and 18 h together
with doxorubicin). Apoptosis was then measured in MCF7 cell
monolayers under normoxic conditions (Monolayer Normoxia),
MCF7 3-D spheroids (Spheroids), and MCF7 cell monolayers under
hypoxic conditions (Monolayer Hypoxia). ***, P < 0.0001 versus
Monolayer Normoxia without YC-1; **, P < 0.01 versus Monolayer
Normoxia without YC-1; °°, P < 0.001 versus Spheroids without YC-1;
°, P < 0.05 versus Monolayer Hypoxia without YC-1. The figures are
representative of three similar experiments, performed in duplicate.
B: Evaluation of apoptosis by detection of caspase activity by
fluorogenic assays measured as amount of cleaved fluorogenic
substrates from cellular lysates by spectrophotometric analysis.
Cleavage of the synthetic fluorogenic substrate Ac-LEDH-AMC by
caspase-9. Cells and spheroids were incubated with 3 μMol/L
doxorubicin for 18 h, in the absence (white columns) or in the
presence (hatched columns) of 5 μMol/L YC-1 for 24 h (6 h alone
and 18 h together with doxorubicin). Apoptosis was then measured
in MCF7 cell monolayers under normoxic conditions (Monolayer
Normoxia), MCF7 3-D spheroids (Spheroids), and MCF7 cell
monolayers under hypoxic conditions (Monolayer Hypoxia). ***, P <
0.0001 versus Monolayer Normoxia without YC-1; **, P < 0.0001
versus Monolayer Normoxia without YC-1; °°, P < 0.001 versus
Spheroids without YC-1; °, P < 0.001 versus Monolayer Hypoxia
without YC-1. The figures are representative of three similar
experiments, performed in duplicate.
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Discussion
Neoadjuvant chemotherapy (NAC) is the standard care
for locally advanced breast cancer and is used increas-
ingly for large breast cancer with the intention of tumor
down-staging so that breast-conserving surgery could be
considered as a surgical option [35-37]. IMPC of the
breast is a distinct and aggressive variant of breast can-
cer that shows marked lymphotropism, extensive axillary
lymph node involvement at diagnosis, and frequent local
recurrence and distant metastases at follow up. In addi-
tion, Alvarado-Cabrero et al. have recently reported that
none of the IMPC of a case series of locally advanced
breast cancers treated by NAC did respond to treatment
[7]. To our knowledge, no data exist on the molecular
basis of the lack of response to chemotherapy in IMPC
of the breast.
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Figure 8 A and B: Hematoxylin and Eosin staining of formalin fixed paraffin embedded MCF7 3-D spheroids . (A, bar 40 microns) The
spheroids had almost the same morphology and diameter of the micropapillae of the carcinoma in breast biopsy from a patient with IMPC (B,
bar 40 microns). C and D: Immunohistochemical staining for MUC1 in formalin fixed paraffin embedded MCF7 3-D spheroids (C, bar 10 microns)
and biopsy from a patient with IMPC of the breast (D, bar 10 microns). E and F: Immunohistochemical staining for HIF1-a in formalin fixed
paraffin embedded MCF7 3-D spheroids (E, bar 12 microns) and biopsy from a patient with IMPC of the breast (F, bar 12 microns). The figures
are representative of three similar experiments.
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In the present study, using a 3-D model that mimics
the small papillae typical of the IMPC growth pattern,
we demonstrated that HIF-1 activation may be related
to the drug resistance described in this tumor. We
decided to use the ER-positive MCF7 cancer cells
because the IMPC are, in most cases, ER-positive breast
cancers.
We first observed that HIF-1a is translocated into the
nucleus and is able to bind a HRE both when MCF7
cells are cultured as 3-D spheroids or as monolayers
under hypoxic conditions. In contrast, MCF7 cell mono-
layers under normoxic conditions exhibit a minimal
activation of HIF-1. We also showed that expression of
PDK1, PGK1, and VEGF, well-known HIF-1 target
genes, was increased in MCF7 3-D spheroids and MCF7
hypoxic cells compared to MCF7 control cells. This
observation suggests that in vitro MCF7 3-D spheroid
formation may mimic hypoxic conditions and that the
activation of HIF-1 in MCF7 3-D spheroids may be an
adaptation to hypoxia. This result is in agreement with
previous reports showing that cells cultured as 3D-
spheroids are associated with a microenvironment char-
acterized by gradients in O2, pH, and nutrients, which
simulates the architecture of tumors better than the 2-D
or monolayer cell culture model [27,28,38].
It has been postulated that hypoxia in solid tumors
dramatically decreases the chemosensitivity of tumor
cells and that experimental hypoxia promotes drug
resistance to anticancer agents in a variety of cell lines
[12]. In particular, Comerford et al. revealed that
hypoxia induces MDR-1 gene expression and concomi-
tant functional expression of its product Pgp in cells
grown as monolayers under hypoxic conditions and in
cells grown as multicellular spheroids. Moreover, they
identified a functional HIF-1 binding site within the
MDR-1 gene promoter [16]. Later on other groups con-
firmed that the activation of HIF-1 in tumor cells is
associated with an increase in Pgp expression [17-20].
These findings are consistent with the present results
reporting that binding of HIF-1a to MDR-1 gene pro-
moter is higher in MCF7 3-D spheroids and in MCF7
hypoxic cells than in MCF7 control cells. In addition,
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Figure 9 A and B: Immunohistochemical staining for CD44 in formalin fixed paraffin embedded MCF7 cell monolayers under
normoxic conditions. . (MCF7 control cells) (A, bar 4 microns) and in MCF7 3D-spheroids (B, bar 4 microns). Spheroids formation induced de
novo acquisition of CD44 that was visible on the cell membrane. C and D: Immunohistochemical for p53. Only few nuclei of MCF-7 control cells
were positive (C, bar 40 microns), while a higher number of positive nuclei were present in MCF7 3D-spheroids (D, bar 40 microns).
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we observed an increased expression of Pgp on the sur-
face of cells obtained from 3-D spheroids and from
monolayers under hypoxic conditions. This increase is
abolished both by the incubation of cells with YC-1,
which induces a decrease in HIF-1a accumulation by
down-regulating HIF-1a mRNA translation [29], and by
the transfection of cells with specific siRNA for HIF-1a.
Our results suggest that in both MCF7 3-D spheroids
and MCF7 hypoxic cells HIF-1 is activated and is
recruited to participate to the transcriptional activity of
MDR-1 gene, and that the increase of Pgp surface-
expression is associated with this activation. It is note-
worthy that Pgp is a predominant membrane transpor-
ter associated with chemotherapy resistance [39]. Here
we demonstrated that MCF7 3-D spheroids and MCF7
hypoxic cells accumulate less doxorubicin and are less
sensitive to its cytotoxic effects than MCF7 cells cul-
tured as a monolayer under normoxic conditions. The
inhibition of HIF-1a, either by incubating cells with YC-
1 or by transfecting cells with specific siRNA for HIF-
1a, increases the doxorubicin accumulation in both
MCF7 3-D spheroids and MCF7 hypoxic cells to a level
comparable to the one of MCF7 control cells, confirm-
ing that HIF-1 activation induces doxorubicin resistance.
It has been previously demonstrated that doxorubicin
induces apoptotic cell death in cancer cell lines [31],
even though doxorubicin has been also reported to
induce senescence in tumour cells [40]. In the present
study, the percentage of annexin V-positive cells and the
caspase-9 activity of MCF7 control cells exposed to dox-
orubicin are low. However, we did not observe in MCF7
control cells enlarged and flattened cells, the predomi-
nant morphologic change associated with the onset of
drug-induced senescence [41], and we observed signifi-
cant differences in percentage of apoptotic cells and cas-
pase-9 activity in the following couples: 1) MCF7
control cells and MCF7 3-D spheroids in the absence of
YC-1; 2) MCF7 3-D spheroids in the absence of YC-1
and MCF7 3-D spheroids in the presence of YC-1.
Moreover, we restricted our interest to doxorubicin
because this drug is widely used to treat ER + breast
cancer in clinical setting.
Recently, Hung et al. demonstrated that YC-1 is able
to modulate the transport function of Pgp and thus to
chemosensitize hypoxic tumor cells via the nitric oxide
(NO)- cyclic GMP (cGMP)- cGMP-dependent protein
kinase (PKG)- extracellular signal-regulated kinase sig-
naling pathway through noncompetitive inhibition [42].
Previous studies have shown that various NO mimetics,
including 8-bromo-cGMP, attenuate hypoxia-induced
resistance to several chemotherapeutic agents including
doxorubicin, suggesting that part of the mechanism of
hypoxia-induced drug resistance in cancer cells is the
suppression of endogenous NO production [43,44].
Moreover, Frederiksen et al. demonstrated that chemo-
sensitization of hypoxic tumor cells by NO mimetics
requires activation of soluble guanylyl cyclase, genera-
tion of cGMP, and activation of PKG [45]. Our research
group has also reported that a doxorubicin-resistant
(HT29-dx) cell population obtained from epithelial
colon cell line HT29 accumulates less intracellular dox-
orubicin, is less sensitive to the cytotoxic effects of the
drug, overexpresses Pgp, and exhibits a lower NO pro-
duction. The resistance to doxorubicin is reversed by
inducers of NO synthesis [46]. In the present study,
even if we cannot exclude that YC-1 activates the NO-
cGMP-PKG signaling pathway, the inhibition of HIF-1a
by transfecting cells with specific siRNA for HIF-1a
seems to confirm the previously reported inhibitory
action of YC-1 on HIF-1a mRNA translation [29].
We demonstrated that the presence of verapamil
restores the intracellular doxorubicin content observed
in MCF7 3-D spheroids to a level comparable to the
one of MCF7 control cells, suggesting that MCF7 3-D
spheroid formation induces a resistance to doxorubicin,
at least in part, via Pgp. However, verapamil, a com-
monly used first-generation Pgp inhibitor, is also able to
inhibit other ABC transporters such as MDR3 and some
multidrug resistance-associated proteins (MRPs) [47].
Verapamil is nevertheless not able to inhibit MRP1 and
the breast cancer resistance protein, two other ABC
transporters associated with a MDR phenotype in cancer
cells [48] and expressed in MCF7 cells (data not shown),
suggesting that Pgp may have an important role in the
MDR phenotype in MCF7 3-D spheroids.
Finally to confirm that our 3D-culture model produces
cell clusters truly similar to IMPC, we evaluated whether
the inside-out growth pattern of IMPC was reproduced in
vitro [49]. The peculiar architecture of IMPC of the breast
has been attributed to a rotation of cell polarization so
that the surface of the tumor cells that faces the stroma
acquires apical secretory properties and detaches from the
stroma. This was shown first by electron microscopy [50]
and then confirmed by immunohistochemical staining for
MUC1 [33]. MUC1 is a glycoprotein normally located in
the apical cell surface of normal glandular epithelium. In
conventional carcinomas MUC1 is largely apical, with
intracytoplasmic or intercellular distribution [51]. In
IMPC, MUC1 has a highly aberrant expression being loca-
lized predominantly in the stroma-facing surface of the
cells [33,34]. In this study, we obtained in vitro 3-D spher-
oids by treating MCF7 cells with human neutrophil elas-
tase, as described previously [21]. We demonstrated that
the morphological similarity observed between MCF7 3-D
spheroids and IMPC of the breast corresponds to a similar
distribution of MUC1. Indeed, in MCF7 3-D spheroids
MUC1 is expressed along the outer cell surface of the
clusters. The mechanism of neutrophil elastase-induced
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formation of MCF7 3-D spheroids with inverted orienta-
tion of epithelial polarity is yet unknown. Moreover, we
showed that MCF7 3-D spheroids express markers of bio-
logical aggressiveness such as CD44 and p53 similarly to
IMPC.
We showed that in breast biopsy from patients with
IMPC HIF-1a is expressed in the nucleus of the cells
similarly to MCF7 3-D spheroids. This result is in agree-
ment with previous reports showing that ER + breast
cancers express strong levels of HIF-1a [52] and its
expression is correlated with diagnostic and prognostic
indicators for early relapse and metastatic disease [53].
Conclusions
The present study demonstrates that the MCF7 breast
cancer cells cultured as 3-D spheroids are resistant to
doxorubicin and that this resistance is associated with
an increased Pgp expression at the plasma membrane
via activation of HIF-1. The observations made with cul-
tured MCF7 3-D spheroids must be interpreted with
caution. Nevertheless, on one hand, MCF7 cells are ER
+ breast cancer cells, are able to form compact multicel-
lular 3D-spheroids when plated in medium containing
human neutrophil elastase, express MUC1 along the
outer cell surface of the clusters, and show increased
CD44 and p53 levels. On the other hand, IMPC of the
breast shows nuclear expression of HIF-1a. So far, the
results of the present study suggest that such spheroids
could be used as a potential in vitro model to investigate
the role of drug resistance in the aggressive behavior of
tumor cell clusters encountered in IMPC of the breast.
Additional material
Additional file 1: Figure S1 Contribution of Pgp to the doxorubicin
resistance in MCF7 cells. Cells and spheroids were incubated with 3
μMol/L doxorubicin for 18 h, in the absence (white columns) or presence
(hatched columns) of 100 μMol/L verapamil (6 h alone and 18 h
together with doxorubicin). Drug accumulation was then measured in
MCF7 cell monolayers under normoxic conditions (Monolayer Normoxia)
and MCF7 3-D spheroids (Spheroids). ***, P < 0.0001 versus Monolayer
Normoxia without verapamil; °°°, P < 0.0001 versus Spheroids without
verapamil.
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Figure S1 Contribution of Pgp to the
doxorubicin resistance in MCF7 cells. 
Cells and spheroids were incubated with 3 µMol/L doxorubicin
for 18 h, in the absence (white columns) or presence
(hatched columns) of 100 µMol/L verapamil
(6 h alone and 18 h together with doxorubicin). 
Drug accumulation was then measured in MCF7 cell
monolayers under normoxic conditions (Monolayer Normoxia)
and MCF7 3-D spheroids (Spheroids). 
***, P < 0.0001 versus Monolayer Normoxia without verapamil;
°°°, P < 0.0001 versus Spheroids without verapamil. 
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